72.03
-0.48 (-0.66%)
| Previous Close | 72.51 |
| Open | 72.71 |
| Volume | 305,331 |
| Avg. Volume (3M) | 461,101 |
| Market Cap | 2,093,038,208 |
| Price / Sales | 10.15 |
| Price / Book | 117.06 |
| 52 Weeks Range | |
| Earnings Date | 5 Nov 2025 |
| Profit Margin | -52.34% |
| Operating Margin (TTM) | -40.96% |
| Diluted EPS (TTM) | -3.12 |
| Quarterly Revenue Growth (YOY) | 11.30% |
| Total Debt/Equity (MRQ) | 585.48% |
| Current Ratio (MRQ) | 3.36 |
| Operating Cash Flow (TTM) | -68.09 M |
| Levered Free Cash Flow (TTM) | -44.94 M |
| Return on Assets (TTM) | -11.43% |
| Return on Equity (TTM) | -186.68% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Mixed |
| Medical Devices (Global) | Mixed | Mixed | |
| Stock | Establishment Labs Holdings Inc | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | 0.88 |
|
Establishment Labs Holdings Inc is a medical technology company engaged in offering medical devices and aesthetic products. It is involved in the designing, manufacturing, and marketing silicone-filled breast and body shaping implants. The company markets its products under Motiva implants Brand. It distributes its products to medical distributors; and physicians, hospitals, and clinics in the form of direct sales. Its geographical segments are Europe, Latin America, Asia-Pacific/Middle East, and Others. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Growth |
| % Held by Insiders | 10.75% |
| % Held by Institutions | 106.06% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 90.00 (Mizuho, 24.95%) | Buy |
| Median | 84.50 (17.31%) | |
| Low | 75.00 (Citigroup, 4.12%) | Hold |
| Average | 83.33 (15.69%) | |
| Total | 5 Buy, 1 Hold | |
| Avg. Price @ Call | 72.75 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Needham | 12 Jan 2026 | 84.00 (16.62%) | Buy | 66.76 |
| 10 Dec 2025 | 84.00 (16.62%) | Buy | 72.46 | |
| BTIG | 31 Dec 2025 | 86.00 (19.39%) | Buy | 72.88 |
| 14 Nov 2025 | 81.00 (12.45%) | Buy | 63.99 | |
| Canaccord Genuity | 17 Dec 2025 | 85.00 (18.01%) | Buy | 74.71 |
| 06 Nov 2025 | 72.00 (-0.04%) | Buy | 64.91 | |
| JP Morgan | 17 Dec 2025 | 80.00 (11.06%) | Buy | 74.71 |
| 06 Nov 2025 | 71.00 (-1.43%) | Buy | 64.91 | |
| Mizuho | 17 Dec 2025 | 90.00 (24.95%) | Buy | 74.71 |
| 06 Nov 2025 | 85.00 (18.01%) | Buy | 64.91 | |
| Citigroup | 11 Dec 2025 | 75.00 (4.12%) | Hold | 72.72 |
| Show more | ||||
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 12 Jan 2026 | Announcement | Establishment Labs Announces Preliminary Unaudited Financial Results for Fourth Quarter and Fiscal Year 2025 |
| 31 Dec 2025 | Announcement | Establishment Labs to Present at 44th Annual J.P. Morgan Healthcare Conference |
| 29 Dec 2025 | Announcement | Establishment Labs Submits to FDA for Approval of Motiva Implants in Breast Reconstruction |
| 07 Nov 2025 | Announcement | Establishment Labs to Present at Jefferies London Healthcare Conference |
| 05 Nov 2025 | Announcement | Establishment Labs Reports Third Quarter 2025 Financial Results |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |